Citations

Clear

4847 citation(s) found for "Tu, Eric".

Recommendations of the German, Austrian and Swiss rheumatology and other medical societies for the management of polymyalgia rheumatica
Buttgereit, Frank , Reisch, Myriam , Brabant, Thomas, Daikeler, Thomas, Duftner, Christina , Erstling, Ulrike , Garske, Ute, Hellmich, Bernhard , Reißhauer, Anett , Reuß‐Borst, Monika , Scheuermann, Karin, Steffens-Korbanka, Patricia , Matteson, Eric L. , Daikeler, Thomas , Hellmich, Bernhard , Kyburz, Diego , Dejaco, Christian , Buttgereit, Frank , Boyadzhieva, Zhivana , Schneider, Matthias , Garske, Ute, Scheuermann, Karin, Dejaco, Christian

Mayo Clinic

Rheumatology | December 3, 2025 | Volume: 65 | Issue: 2 | Pages: No page available

10.1093/rheumatology/keaf646 | PMID 41346249 Get It

Abstract Objectives Polymyalgia rheumatica (PMR) is the second most frequent inflammatory rheumatic disease in older adults, after rheumatoid arthritis. Recommendations for the management of PMR, developed by the German, Austrian and Swiss societies of rheumatology and other organizations were published in 2018. Methods These recommendations are now updated based on a systematic literature search that covered the evidence published between July 2016 and January 2024 on therapeutic interventions and prognostic factors for PMR. The search string followed that used in the original recommendations, with an extension for targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Based on evidence and expert opinions, the task force (12 physicians, two healthcare professionals and two patients from three countries) developed a set of four overarching principles and seven specific recommendations. Results The current update reiterates previous guideline recommendations for glucocorticoids (15–25 mg prednisone equivalents per day) as initial treatment for PMR once diagnosis has been confirmed, with subsequent tapering over 4–12 months (depending on whether a glucocorticoid sparing agent is used), with monitoring of disease activity and treatment-related adverse effects. Interleukin-6 receptor blocking agents should be considered in addition to glucocorticoids in patients with relapsing disease and can be considered in patients with new-onset PMR at high risk for glucocorticoid-related adverse events. Methotrexate or rituximab may be alternatives. Older and frail patients should also be offered an individualized exercise program. Conclusion These updated recommendations should serve as an aid to evidence-based decisions ensuring high-quality care for all patients with PMR.
Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study
Feldman, Andrew L. , Dasari, Surendra, Scott, David W. , Oishi, Naoki , Hu, Guangzhen , Farinha, Pedro , Amador, Catalina , Campo, Elı́as , Cook, James R. , Fu, Kai , Greiner, Timothy C. , Iqbal, Javeed , Ondrejka, Sarah L. , Ott, G., Rosenwald, Andreas , Slack, Graham W. , Wright, George, Zeng, Yu , Yoshino, Tadashi, Wu, Xiaojun , Satou, Akira , Perry, Anamarija M. , Mou, Eric , Ko, Young Hyeh , Jiang, Liuyan , Gru, Alejandro A. , Chen, Weina , Chapman, Jennifer R. , Ansell, Stephen M. , Aljudi, Ahmed Assim , Scott, David W , Oishi, Naoki , Farinha, Pedro , Amador, Catalina , Campo, Elías , Cook, James R , Delabie, Jan , Greiner, Timothy C , Hilton, Laura K , Inghirami, Giorgio , Jaffe, Elaine S , Morin, Ryan D , Ondrejka, Sarah , Pittaluga, Stefania , Savage, Kerry J , Slager, Susan L , Wang, Hao-Wei , Wu, Xiaojun , Wilcox, Ryan A , Shi, Min , Miranda, Roberto N , Medeiros, L Jeffrey , Maurer, Matthew , Mou, Eric , Karube, Kennosuke , Gru, Alejandro , de Leval, Laurence , Chen, Weina , Cerhan, James R , Barrionuevo, Carlos , Aljudi, Ahmed Assim , Feldman, Andrew L , Iqbal, Javeed , Rimsza, Lisa M. , Chan, Wing C., Delabie, Jan , Hilton, Laura K. , Inghirami, Giorgio , Jaffe, Elaine S. , Pittaluga, Stefania , Raess, Philipp W. , Savage, Kerry J. , Slager, Susan L. , Song, Joo Y. , Wang, Hao‐Wei , Wilcox, Ryan A. , Wang, Xueju , Miranda, Roberto N. , Medeiros, L. Jeffrey , Maurer, Matthew J. , Karube, Kennosuke , Kahl, Brad S. , Jaye, David L. , Leval, Laurence de , Cerhan, James R.

Mayo Clinic

Blood | December 2, 2025 | Volume: 147 | Issue: 11 | Pages: 1199-1214

10.1182/blood.2024027700 | PMID 41329859 Get It

Abstract Anaplastic large cell lymphomas (ALCLs) are CD30+ T-cell lymphomas that share pathologic features but differ in presentation, outcome, and genetics. Current classification incorporates clinical presentation and anaplastic lymphoma kinase (ALK) status but inadequately addresses molecular heterogeneity and therapeutic vulnerabilities. We studied 689 patients with ALCL in the LLMPP (Lymphoma/Leukemia Molecular Profiling Project) and performed expert consensus review, genetic subtyping (ALK, DUSP22, TP63, and triple negative), and immunohistochemistry for phosphorylated STAT3Tyr705. RNA sequencing with unsupervised gene expression profiling in 393 patients identified 2 main molecular types of ALCL that could be predicted with 91% accuracy based on the presence (type I) or absence (type II) of phosphorylated STAT3Y705 expression. Type I ALCLs included ALK+ ALCL and a subset of triple-negative ALCLs (TN-I); type II ALCLs included tumors with DUSP22 and/or TP63 rearrangements and the remaining triple-negative ALCLs (TN-II). Type I ALCLs were enriched for JAK-STAT3, whereas type II ALCLs were enriched for non–tyrosine kinase pathways, particularly epigenetic regulators such as EZH2. Immunohistochemistry showed overexpression of EZH2 and its trimethylated substrate H3K27. Prognosis in systemic ALCL was favorable for DUSP22-rearranged ALCL (5-year overall survival, 95%) and ALK+ ALCL (88%), intermediate for triple-negative ALCL (TN-I, 52% and TN-II, 37%), and poor for TP63-rearranged ALCL (0%). We introduce an integrated molecular classification that preserves currently diagnosed ALCL entities but identifies 4 molecularly distinct ALK− ALCL subtypes (DUSP22-rearranged, TP63-rearranged, TN-I, and TN-II). This classification can be easily implemented on paraffin tissue in routine practice or clinical trials, and stratifies ALCL into diagnostically, prognostically, biologically, and potentially therapeutically relevant subtypes.
Abstract 290: Treatment Strategies for Residual and Recurrent Aneurysms After Woven EndoBridge Therapy: A Multicenter Propensity‐Matched Analysis
Gudino, Andres, Reddi, Preethi , Sridhar, V., Haranhalli, Neil , Karandish, Alireza , Aghaebrahim, Amin, Sauvageau, Eric , Crowley, W F, Dabus, Guilherme , Paul, A.R. , Puri, A, Rinaldo, Lorenzo , Brinjikji, Waleed , Goren, Oded , Siddiqui, Adnan, Jaikumar, Vinay , Essibayi, Muhammed Amir , Gutierrez‐Aguirre, Salvador F. , Hendrix, Philipp , Ransom, Ryan C. , Gudino, Andres , Ringer, Andrew J. , Kühn, Anna Luisa , Field, N., Ríos-Zermeño, Jorge , Amllay, Abdelaziz , Monteiro, Andre , Khatri, Deepak , Toledo, Otavio F. De , Crowley, W., Dabus, Guilherme C. , Matouk, Charles , Tawk, Rabih G. , Paul, A. R., Mocco, J , Majidi, Shahram , Samaniego, Edgar A , Lanzino, Giuseppe , Hanel, Ricardó A. , Altschul, David , Levy, Elad I.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_290 Get It

Introduction Post‐market and multicenter studies report low complete occlusion rates (41‐49%) and higher retreatment rates (13%) following WEB deployment, compared to 3.8% with microsurgical clipping. While retreatment after WEB has been shown to be technically feasible, data on final angiographic outcomes remain limited. We performed a retrospective analysis of prospective databases from 14 cerebrovascular centers in the US to compare the safety and efficacy of retreatment versus continued observation for residual and recurrent aneurysms after initial WEB deployment. Materials/Methods Multinomial logistic regression was used to identify baseline characteristics of untreated and residual/recurrent aneurysms that may act as confounders, which then underwent propensity scored matching (PSM). Results Among 211 patients (125 observed, 86 retreated), retreatment was more common in initially ruptured aneurysms (p<0.001), which showed higher recurrence (p=0.036) and sac‐dominant residuals (p=0.004). These were primarily due to WEB compression on follow‐up (p=0.001), rather than incomplete occlusion with an appropriately sized device (p<0.001). Retreatment was associated with significantly higher rates of complete angiographic occlusion at last follow‐up compared to observation alone (p<0.001), a finding that remained consistent across subgroups defined by initial unruptured status, residual type, and recurrence patterns (all p<0.05). Clipping demonstrated higher, though statistically insignificant, rates of complete occlusion; flow diversion and stent‐assisted coil embolization yielded comparable complete occlusion rates at follow‐up. After propensity score matching, retreatment remained significantly associated with higher rates of complete angiographic occlusion (all p<0.05), with comparable outcomes observed between clipping and various endovascular approaches as above. Conclusion Retreatment improved complete occlusion rates; however, no aneurysmal hemorrhages occurred in either group. Further intervention may be unnecessary when the WEB device—whether compressed or intact (BOSS 0/1)—adequately protects the dome. In cases where WEB compression significantly exposes the aneurysm wall, stent‐assisted coiling or flow diversion can be performed safely and successfully, depending on vascular anatomy and surgeon preference. image image
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Walbert, Tobias , Lassman, Andrew B. , Peereboom, David M. , Kizilbash, Sani H. , Matsuoka, Carlos Kamiya , Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Butowski, Nicholas , Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Wang, Chao , Levin, Victor A. , Lassman, Andrew B , Peereboom, David M , Kizilbash, Sani H , Kamiya-Matsuoka, Carlos , Pitz, Marshall W , Strowd, Roy E , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Soffietti, Riccardo , Butowski, Nicholas A , Forsyth, Peter A , Hamza, Mohamed A , Hau, Peter , Nabors, Louis Burt , Uhlmann, Erik J , Welsh, Liam C , Wen, Patrick Yung , Dietrich, Jorg , Wang, Chao , Levin, Victor A , Colman, Howard , Eoli, Marica , Strowd, Roy E. , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Lombardi, G

Mayo Clinic

Journal of Clinical Oncology | December 1, 2025 | Volume: 44 | Issue: 8 | Pages: 641-652

10.1200/jco-25-01204 | PMID 41325560 Get It

PURPOSE STELLAR (ClinicalTrials.gov identifier: NCT02796261 ) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase ( IDH ) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m 2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m 2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m 2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH- mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH -mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.
Hypoxemia and arousals modulate cardiac responses to respiratory events in obstructive sleep apnea
Ebrahimian, Serajeddin , Rissanen, Marika , Staykov, Eric , Kulkas, Antti , Töyräs, Juha , Grote, Ludger , Baumert, Mathias , Terrill, Philip I. , Staykov, Eric , Kulkas, Antti , Grote, Ludger , Baumert, Mathias , Somers, Virend K. , Leppänen, Timo , Kainulainen, Samu , Sillanmäki, Saara , Bailón, Raquel , Bonsignore, Maria Rosaria , Somers, Virend K.

Mayo Clinic

SLEEPJ | November 30, 2025 | Volume: 49 | Issue: 3 | Pages: No page available

10.1093/sleep/zsaf382 | PMID 41324441 Get It

Abstract Study Objectives Respiratory events during sleep induce immediate cardiac alterations, including increased RR intervals during events and decreased RR intervals after events. However, the extent to which related desaturations and arousals modulate these responses remains underexplored. We hypothesized that desaturations and arousals are the main contributors to respiratory event-related cardiac response, with greatest cardiac alterations expected when both are present. Methods We analyzed RR, QT, and heart rate-corrected QT (QTc) intervals before, during, and after 4310 respiratory events from 129 obstructive sleep apnea patients. Mixed-effect statistical models were utilized to assess the influence of the presence and severity of desaturations and arousals on the cardiac electrical response to respiratory events. Results There were no significant differences between pre- and post-respiratory event RR and QTc intervals in the absence of desaturation or arousal. Arousal (RR estimate = −23.9 ms; QTc estimate = 5.7 ms) or simultaneous desaturation and arousal (RR estimate = −32.8 ms; QTc estimate = 8.4 ms) modulated significantly (p &lt; .05) mean RR and QTc intervals after respiratory events. Desaturation alone affected only RR intervals (estimate = −9.3 ms, p&lt;.05). Greater desaturation depth (RR estimate = −0.09 ms; QTc estimate = 0.56 ms) and longer arousal duration (RR estimate = −3.52 ms; QTc estimate = 0.84 ms) were significant (p &lt; .05) predictors of RR and QTc magnitude alterations after respiratory events. Conclusions Not all respiratory events have the same effects on cardiac electrophysiology; they are associated with acute alterations after events if they cause desaturations and/or arousal, with longer arousal and deeper desaturations increasing the magnitude of cardiac responses. Statement of Significance This study provides a detailed analysis of the temporal dynamics of cardiac response to respiratory events in obstructive sleep apnea patients, with a focus on the potential modulators of this response. Our observations present that not all respiratory events have the same effects on cardiac electrophysiology; they are associated with significant cardiac response if they cause desaturations and/or arousals, with longer arousal and deeper desaturations increasing the magnitude of cardiac response. Our results present evidence of possible modulators of post-event cardiac function, providing a deeper understanding of obstructive sleep apnea’s impact on health as potential underlying mechanisms leading to adverse cardiovascular events.
Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study
Croitoru, David , Brahimi, N. , Zabihi, Haleh , Seigel, Kyle , Shojaei, Delaram , McMullen, Eric , Alavi, Afsáneh , Archaempong, Lily , Drucker, Aaron M. , Weizman, Adam V. , Croitoru, Kenneth , Alavi, A , Croitoru, D , Sibbald, Cathryn , Inman, Robert Davies , Piguet, Vincent

Mayo Clinic

JEADV Clinical Practice | November 29, 2025 | Volume: 5 | Issue: 2 | Pages: 495-501

10.1002/jvc2.70227 Get It

ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary wound care centre. Methods A prospective observational study was conducted of patients referred for suspected PG between April 2021 and June 2023. Demographic, clinical and laboratory data, including biopsies and tissue cultures, were collected. Patients were categorised as having PG vs alternative diagnoses based on diagnostic criteria from Su, Maverakis and the PARACELSUS score. Results Of 60 patients (female, 51.7%; mean [SD] age 52.9 [14.0] years), 44 (73.3%) met at least one published diagnostic criterion for PG. The most common comorbidity was IBD (63.6%), followed by inflammatory arthritis (25.0%) and monoclonal gammopathy of undetermined significance (MGUS) (4.5%). Systemic corticosteroids were used by 40.9% of patients before referral, but steroid‐sparing agents and biologics were the primary treatments after consultation. Biologics and steroid‐sparing agents were associated with significant improvement in disease activity using the PGA score (average score decreased from 2.3 to 1.5, p < 0.005), with 40.9% achieving complete remission. Elevated serum inflammatory markers and faecal calprotectin were observed in PG patients but absent in non‐PG cases. Conclusions These prospective data support previously published rates of association between PG and systemic comorbidities. Steroid‐sparing anti‐neutrophilic and targeted therapies are effective steroid‐sparing strategies in managing PG. Small sample size and referral bias may limit generalisability.
Developing Global Gastrointestinal Care Capacity
Bryan, Matthew R , Bensen, Gordon P. , Wipper, Benjamin , Felicien, Shikama, Ingabire, Prosper, Rutaganda, Eric , Smith, Matthew , Laird, Rebecca, Makrauer, Frederick, Rubenberg, Lisa A, Chudy‐Onwugaje, Kenechukwu , Gardner, Timothy B. , Duerksen, Donald R. , Bensen, Steven P., Dusabejambo, Vincent , Dunleavy, Katie A. , Felicien, SHIKAMA, Makrauer, Frederick L., Bensen, Steve P.

Mayo Clinic

Journal of Clinical Gastroenterology | November 26, 2025 | Volume: 60 | Issue: 1 | Pages: 1-9

10.1097/mcg.0000000000002274 | PMID 41295906 Get It

Goals: Describe the establishment and expansion of a global gastrointestinal (GI) partnership and its impact on the advancement of GI care in Rwanda. Background: GI disease disproportionately affects low- and middle-income countries. In Rwanda, governmental and nonprofit efforts have made significant progress in expanding access to health care in the wake of the 1994 genocide; however, specialized care remains largely unrecognized or inaccessible. In response, the Rwanda Ministry of Health established a partnership with an international gastroenterology NGO to address this critical need. Study: We present summative data generated by this partnership. To inform future global GI programs, we provide lessons learned and details about Rwanda’s successful establishment of an in-country, self-sustainable, and locally governed gastroenterology training program. Results: From 2017 to 2023, the partnership expanded the number of clinical sites receiving care from 4 to 11. Total procedural volume increased from 244 to 1069. Most common presenting upper GI symptoms included dyspepsia, reflux, and emesis, while most common lower GI symptoms included hematochezia and constipation. Since 2017, this partnership has increased the number of faculty volunteering in Rwanda (and Rwandan clinicians studying in US academic medical centers), expanded its geographical reach, assisted in the creation of a GI fellowship, and enabled Rwanda to become an East African hub for medical education. Conclusions: Lessons learned across ethical, financial, leadership, cultural, and medical domains from the successful establishment and expansion of an international GI partnership in Rwanda provides invaluable insights to guide development of future models of health care in emerging economies.
Patient Characteristics and Outcomes of Cardiac Rehabilitation Following Thoracic Aortic Dissection Surgery: A Multicenter Retrospective Study
Heybati, Kiyan , Ochal, Domenic, Poudel, Keshav , Zuberi, Eric , Deng, Jiawen , Dineen, Elizabeth H. , Brahmbhatt, Pavan M., Daugherty, David H., Farres, Sam, Landolfo, Kevin, Bonikowske, Amanda R. , Mergo, Patricia J. , Shapiro, Brian P. , Deng, J , Taylor, Bryan J. , Brahmbhatt, Pavan M., Landolfo, Kevin , Thomas, Randal J.

Mayo Clinic

Journal of Cardiopulmonary Rehabilitation and Prevention | November 26, 2025 | Volume: 46 | Issue: 1 | Pages: 50-57

10.1097/hcr.0000000000000982 | PMID 41294921 Get It

Purpose: Despite the 2022 American Heart Association/American College of Cardiology guidelines recommending cardiac rehabilitation (CR) after aortic dissection repair, both patient participation in CR and the associated clinical outcomes remain poorly understood. Methods: Adults (≥18 years of age) discharged alive following thoracic aortic dissection surgery across the Mayo Clinic Enterprise (January 2012 to November 2022), with follow-up until May 2024, were included (IRB #24-001141). Data were presented using summary statistics and logistic regression modeling. Results: A total of 186 patients were referred; 37% were female, and the median age was 64 (51, 73) years. Dissections were classified as type A (43%), type B (18%), or a combination, and 55% had residual dissection. Over half (53%) did not start CR, with older age (aOR = 0.97: 95% CI, 0.94 - 0.99; P = .003), family history of aortic dissections and/or aneurysms (aOR = 0.17: 95% CI, 0.04 - 0.54; P = .005), and tobacco use (aOR = 0.35: 95% CI, 0.13 - 0.91; P = .037) being associated with lower odds of enrollment. Of the 87 who enrolled, 34 did so at a Mayo Clinic facility. There were no complications, with no difference in adverse outcomes. Among those with evaluations at graduation from CR (n = 21), quality of life (Dartmouth index 16 [14, 19] vs 25 [22, 30]; P = .002) and 6-minute walk distance (488 [375, 531] vs 302 [235, 398] m; P = .001) improved. Conclusions: Following thoracic aortic dissection repair, CR significantly improved quality of life and functional capacity without adverse events. Further work is needed to improve enrollment and establish data-driven safety margins for exercise.
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Pl
Khanna, Dinesh , Spino, Cathie , Kleerup, Eric C., Harui, Airi, Ibrahim, Grace, Kim, Grace Hyun J. , Huang, Suiyuan, McLain, Richard, Tu, Yi‐Hsuan, Steen, Virginia , Weigt, S. Samuel , Lee, Joyce , Fischer, Aryeh , Scholand, Mary Beth , Gordon, Jessica , Dellaripa, Paul F. , Rosas, Iván O. , Hunninghake, Gary M. , Trojanowski, Marcin A. , Dematte, Jane E. , Hsu, Vivien , Domsic, Robyn T. , Raghu, Ganesh , Boente, R. , Roth, Michael D. , Investigators, the Scleroderma Lung Study III, Kim, Grace Hyun J , Nagaraja, Vivek , Silver, Richard M. , Gordon, Jessica K , Dellaripa, Paul F , Domsic, Robyn T , Mayes, Maureen D , Boente, Ryan D , Roth, Michael D , Khanna, Dinesh , Lee, Joyce S , Hunninghake, Gary M , Tashkin, Donald P. , Bernstein, Elana J. , Goldin, Jonathan , Nagaraja, Vivek , Simms, Robert W. , Mayes, Maureen D. , Investigators, the Scleroderma Lung Study III

Mayo Clinic

ACR Open Rheumatology | November 26, 2025 | Volume: 7 | Issue: 12 | Pages: No page available

10.1002/acr2.70126 | PMID 41294296 Get It

Objective Mycophenolate mofetil (MMF) can stabilize or improve lung function in systemic sclerosis–related interstitial lung disease (SSc‐ILD). We hypothesized that combining MMF with pirfenidone (PFD) would produce a significantly more rapid and/or greater improvement in lung function. Methods A randomized (1:1), double‐blind, placebo (PLA)‐controlled phase 2 trial was conducted in SSc‐ILD in which patients received PFD or PLA (801 mg three times daily) along with MMF (1,500 mg twice daily) for 18 months. The primary outcome was change in percent predicted forced vital capacity (FVC‐%). Linear mixed‐effects models assessed treatment differences in a modified intention‐to‐treat population. Results Only fifty‐one of 150 intended subjects (34%) were randomized (MMF+PLA, n = 24; MMF+PFD, n = 27). The FVC‐% improved from baseline to 18 months by 2.24 ± 1.35 (least‐squares mean [LSM] ± SEM) in the MMF+PLA group and 2.09 ± 1.28 in the MMF+PFD group (LSM treatment difference −0.14; P = 0.93). Median time to achieve a ≥3% improvement in FVC‐% was numerically faster in the MMF+PFD versus MMF+PLA group (12.3 vs 17.8 months, respectively), but the difference was not significant ( P = 0.33). For secondary outcomes, only the change over 18 months in the Patient‐Reported Outcomes Measurement Information System 29‐item physical function score, favoring MMF+PFD, reached statistical significance ( P = 0.04). Although other related patient‐reported outcomes (PROs) numerically favored the MMF+PFD group, as did quantitative high‐resolution computed tomography measures of ILD, the differences between groups did not reach statistical significance. Early withdrawals from study medication and adverse events of special interest were numerically greater with MMF+PFD (n = 8 vs 2 and n = 20 vs 7, respectively). Conclusion In this underpowered study, there was no statistically significant treatment difference in overall change in FVC‐% between groups. MMF+PFD was not as well tolerated as MMF+PLA.
A Diagnostic Journey through a Rare Hemostatic Disorder
Oviol, Zaraith Sanchez, Sorensen, Eric S, Carmona, P Joy, Zumberg, Marc , Smock, Kristi J. , Moser, Karen , Chen, Dong , Harris, Neil S , Marin, Maximo J , Chen, Dong , Carmona, Pablo

Mayo Clinic

The Journal of Applied Laboratory Medicine | November 25, 2025 | Volume: 11 | Issue: 3 | Pages: 655-660

10.1093/jalm/jfaf195 | PMID 41791891 Get It